Scleroderma, or systemic sclerosis (SSc), is an autoimmune connective tissue disorder characterized by inflammation, fibrosis and vasculopathy. Right heart failure caused by pulmonary arterial hypertension (PAH) is the leading cause of death in individuals with SSc, and approximately 10 to 15% of individuals with SSc will develop associated PAH (SSc-PAH). The combination of medical treatment options and systematic, routine screening has improved two-year survival for SSc-PAH, yet current screening tools are inadequate and the condition continues to remain under-diagnosed until it is too late. Preliminary data I have obtained demonstrate that even though resting PA pressures may be normal in SSc-PAH patients, hemodynamic evaluation during bicycle ergometry may unveil occult PAH. In fact, my preliminary data show 12 % of SSc patients with normal resting intra-cardiac pressures developed exercise pulmonary hypertension (mean pulmonary artery pressure e25 mmHg, pulmonary capillary wedge pressure d15 mmHg). In order to understand potential mechanisms which may contribute to the development of PAH, our laboratory has focused on the role of specific cell surface enzymes responsible for the catalytic degradation of purine nucleotides, which my mentor's group has shown to be critical regulators of thrombosis and inflammation at the vessel wall/blood interface. One of these ectoenzymes, CD39, is found on the surface of endothelial cells and leukocytes. In my own published data, I have shown that CD39 can be specifically measured on plasma microparticles obtained from patients with PAH. In fact, these microparticles retain their catalytic activity, and are surprisingly elevaed in patients with PAH compared with controls.6 My preliminary data also indicates that alterations in the concentrations of plasma nucleotides and adenosine (the CD39-mediated metabolites of ATP dephosphorylation) may contribute to pulmonary hypertension. These preliminary data lead me to hypothesize that a combination of early hemodynamic factors, right ventricular strain, and circulating plasma biomarkers can be used to identify patients with sub-clinical SSc-PAH who are at risk for the development of overt SSc-PAH. This proposal will study 225 patients with SSc who are at risk for developing PAH, as well as 75 healthy controls, to determine the extent to which hemodynamic parameters, echocardiographic markers of RV strain, and novel plasma microparticle and nucleotide biomarkers obtained at rest and during exercise can predict the development of SSc-PAH. I will complete this project under the mentorship of physician researchers with domain expertise in vascular biology, pulmonary arterial hypertension, SSc, biomarkers and bioinformatics, all of whom have strong track records of training and peer-reviewed funding. My project and relevant didactic coursework will serve as a training vehicle for me during this career development award by enabling me to learn elements of patient recruitment, data management, statistical analysis, acquisition/interpretation of meaningful hemodynamic and echocardiographic research data, and laboratory based analysis of plasma-based biomarkers of disease progression. This program, including didactic, immersive, and mentored components, will prepare me for an independent research career in patient-oriented research.

Public Health Relevance

Scleroderma-associated pulmonary arterial hypertension (SSc-PAH) is a devastating condition that affects up to 15% of patients with scleroderma, with two-year survival rates of only 40% in untreated individuals. Screening for SSc-PAH has lead to improved survival, but current strategies continue to under-diagnose the condition in its earliest, most treatable stage. The overarching goal of this proposal is to use novel markers obtained during exercise to detect SSc-PAH at its earliest stage.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
5K23HL119623-03
Application #
9186559
Study Section
Special Emphasis Panel (ZHL1-CSR-X (O1))
Program Officer
Colombini-Hatch, Sandra
Project Start
2014-12-01
Project End
2019-11-30
Budget Start
2016-12-01
Budget End
2017-11-30
Support Year
3
Fiscal Year
2017
Total Cost
$193,397
Indirect Cost
$13,397
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Rattan, Rahul; Bhattacharjee, Somnath; Zong, Hong et al. (2017) Nanoparticle-macrophage interactions: A balance between clearance and cell-specific targeting. Bioorg Med Chem 25:4487-4496
Sutton, Nadia R; Hayasaki, Takanori; Hyman, Matthew C et al. (2017) Ectonucleotidase CD39-driven control of postinfarction myocardial repair and rupture. JCI Insight 2:e89504
Bhave, Nicole M; Visovatti, Scott H; Kulick, Brian et al. (2017) Right atrial strain is predictive of clinical outcomes and invasive hemodynamic data in group 1 pulmonary arterial hypertension. Int J Cardiovasc Imaging 33:847-855
Visovatti, Scott H; Hyman, Matthew C; Goonewardena, Sascha N et al. (2016) Purinergic dysregulation in pulmonary hypertension. Am J Physiol Heart Circ Physiol 311:H286-98
Kanthi, Yogendra; Hyman, Matthew C; Liao, Hui et al. (2015) Flow-dependent expression of ectonucleotide tri(di)phosphohydrolase-1 and suppression of atherosclerosis. J Clin Invest 125:3027-36
Visovatti, Scott H; Distler, Oliver; Coghlan, J Gerry et al. (2014) Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. Arthritis Res Ther 16:493